다한증 치료 : 시장 점유율 분석, 산업 동향, 통계, 성장 예측(2025-2030년)

The hyperhidrosis treatment market is valued at USD 693.23 million in 2025 and on track to reach USD 908.61 million by 2030, reflecting a 5.56% CAGR.

Rising demand for long-lasting, minimally invasive options such as microwave thermolysis, the first-in-class topical anticholinergic sofpironium bromide, and needle-free toxin delivery systems is creating fresh competitive pressure. Regulatory momentum in the United States and Japan has accelerated product launches, while direct-to-consumer telehealth platforms are normalizing diagnosis and expanding access. Providers are also repositioning offerings around the psychological relief that effective therapy delivers, a message endorsed by recent anxiety-outcome studies. Together these forces are reshaping pricing, adoption rates, and product development priorities across the hyperhidrosis treatment market.

Global Hyperhidrosis Treatment Market Trends and Insights

FDA approval wave of novel topical anticholinergics in the US & Japan

The 2024 US clearance of sofpironium bromide 12.45% gel, following Japan's 2020 nod for the 5% formulation, ended a decade-long drought in new chemical entities for primary axillary disease. Trial data showed 85% of patients achieved clinically meaningful sweat reduction without serious adverse events, elevating confidence among prescribers. Investment has since surged into the topical pipeline, and peak-sales forecasts of USD 474 million in the United States alone are prompting rivals to recalibrate prices and marketing messages.

Rising demand for minimally invasive microwave thermolysis

Microwave thermolysis eliminates sweat glands in a single outpatient session for 90% of candidates, cutting the previous two-session protocol in half and improving cost-effectiveness. Quality-of-life scores rise markedly; median Dermatology Life Quality Index fell from 10 to 4 three months post-procedure . Clinicians view the modality as a premium upgrade to botulinum toxin for patients seeking lasting outcomes.

Social-stigma-driven treatment uptake & awareness campaigns in North America

The International Hyperhidrosis Society reframed hyperhidrosis as a mental-wellness issue through 2024 partnerships with WHO and Eastern Virginia Medical School, highlighting that 75% of sufferers report social impairment yet only 49% discuss symptoms with clinicians. This shift has triggered a spike in self-referrals via telehealth, expanding the diagnosed population well beyond historical estimates.

Other drivers and restraints analyzed in the detailed report include:

1. Rising demand for minimally invasive microwave thermolysis
2. Compensatory sweating & adverse events post-sympathectomy

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Botulinum toxin A injections remained the largest revenue generator in 2024, accounting for 32.13% of the hyperhidrosis treatment market share, supported by broad physician familiarity and consistent short-term efficacy. While repeat dosing drives steady revenue, patient preference is shifting toward treatments with durable outcomes. Microwave thermolysis is therefore climbing at a 6.2% CAGR, propelled by evidence of 82% average sweat reduction and high satisfaction. Regulatory green lights for sofpironium bromide have revived the topical category, attracting investment into gels, creams, and wipes that aim to bridge the gap between OTC antiperspirants and invasive procedures.

The hyperhidrosis treatment market size for microwave thermolysis is projected to widen as single-session protocols improve perceived value. Iontophoresis devices hold a stable foothold in palmar and plantar disease, while oral agents with milder side-effect profiles are re-entering treatment algorithms. Early-stage work on fractional radiofrequency microneedling and needle-free botulinum toxin may create further realignment later in the decade.

Primary focal hyperhidrosis commanded 75.35% of 2024 revenue because of its higher incidence and well-established care pathways. Patients usually begin therapy in adolescence and remain in treatment for decades, providing an annuity-like revenue stream. Secondary generalized hyperhidrosis, often triggered by medication or comorbidity, is the fastest-growing category at 5.9% CAGR. Improved electronic health record prompts now flag excessive sweating as a potential drug side effect, funneling older polypharmacy patients into specialty care.

Precise classification is guiding differentiated regimens: systemic pharmacotherapy to remove triggers in secondary disease and localized devices or topicals for primary focal cases. In turn, the hyperhidrosis treatment market size for systemic drugs is expanding while device makers tailor features to focal areas. Heightened awareness among geriatricians is expected to sustain segment momentum through 2030.

The Hyperhidrosis Treatment Market Report Segments the Industry Into by Treatment Type (Iontophoresis Devices, and More), by Disease Type (Primary Focal Hyperhidrosis, and More), Site of Hyperhidrosis (Palmar and More), End User (Hospitals, and More), Distribution Channel (Hospital Pharmacies, and More) and Geography. The Market Sizes and Forecasts are Provided in Terms of Value (USD).

Geography Analysis

North America led with 42% of 2024 revenue, anchored by robust diagnosis rates and fast regulatory approvals. The 2024 clearances of sofpironium bromide gel and the sodium patch diversified first-line therapy and underscored the region's role as a launch pad for innovation. Aggressive direct-to-consumer advertising by telehealth brands continues to identify previously undiagnosed sufferers, enlarging the treatment base. Payer coverage remains favorable for botulinum toxin and is gradually extending to microwave thermolysis when clinically justified.

Europe presents a mature yet expanding environment. Wide adoption of iontophoresis and toxin therapy persists, while glycopyrronium bromide 1% cream secured authorization across 12 countries, reflecting regulator responsiveness to non-invasive choices. Clinicians increasingly deploy validated quality-of-life indices when selecting therapy, reinforcing patient-centric care models.

Asia-Pacific books the fastest regional CAGR at 6.9%, thanks to Japan's early embrace of topical anticholinergics and China's focus on premium care in urban hubs. South Korea and Australia are piloting tele-pharmacy pathways that could accelerate prescription fulfillment. Middle East and South America, though smaller, register solid mid-single-digit growth as private clinics target youthful demographics seeking confidence in social and professional settings.

1. Abbvie
2. Sientra Inc. / miraDry Inc.
3. Eli Lilly and Company
4. Merz Pharma
5. Brickell Biotech
6. Dermavant Sciences Inc.
7. Candesant Biomedical Inc.
8. Dermadry Laboratories
9. SweatBlock LLC
10. RA Fischer Co.
11. Hidrex GmbH
12. Hidroxa AB
13. GlaxoSmithKline Consumer Healthcare (Certain Dri)
14. Carpe Lotions LLC
15. Strathspey Crown Holdings (Cynosure)
16. Revance Therapeutics
17. Advin Health Care
18. Dermata Therapeutics
19. 1315 Capital

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 FDA Approval Wave of Novel Topical Anticholinergics in the US & Japan
  • 4.2.2 Rising Demand for Minimally-Invasive Microwave Thermolysis
  • 4.2.3 Social-Stigma-Driven Treatment Uptake & Awareness Campaigns in North America
  • 4.2.4 Increasing Prevalence of Secondary Hyperhidrosis Condition
  • 4.2.5 Growth of Digital-Health Platforms Enabling Direct-to-Consumer Diagnosis
  • 4.2.6 Increasing Pipeline of Injectables and Topical Anticholinergics
• 4.3 Market Restraints
  • 4.3.1 Compensatory Sweating & Adverse Events Post-Sympathectomy
  • 4.3.2 High Capital Cost & Limited Reimbursement
  • 4.3.3 Supply Chain Disruptions of Glycopyrronium Cloths in EU & US
  • 4.3.4 Short-Duration Efficacy of Botulinum Toxin Necessitating Repeat Sessions
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Outlook
• 4.6 Porter's Five Forces Analysis
  • 4.6.1 Threat of New Entrants
  • 4.6.2 Bargaining Power of Buyers
  • 4.6.3 Bargaining Power of Suppliers
  • 4.6.4 Threat of Substitute Products
  • 4.6.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value / Volume)

• 5.1 By Treatment Type
  • 5.1.1 Topical Antiperspirants & Anticholinergics
  • 5.1.2 Botulinum Toxin A Injections
  • 5.1.3 Iontophoresis Devices
  • 5.1.4 Microwave Thermolysis (miraDry)
  • 5.1.5 Endoscopic Thoracic Sympathectomy (ETS) Surgery
  • 5.1.6 Laser & Energy-based Therapies
  • 5.1.7 Oral Medications
  • 5.1.8 Other Treatment Types
• 5.2 By Disease Type
  • 5.2.1 Primary Focal Hyperhidrosis
  • 5.2.2 Secondary Generalized Hyperhidrosis
• 5.3 By Site of Hyperhidrosis
  • 5.3.1 Axillary (Underarms)
  • 5.3.2 Palmar (Hands)
  • 5.3.3 Plantar (Feet)
  • 5.3.4 Craniofacial
  • 5.3.5 Others (Trunk, Groin)
• 5.4 By End User
  • 5.4.1 Hospitals
  • 5.4.2 Dermatology & Aesthetic Clinics
  • 5.4.3 Ambulatory Surgical Centers
  • 5.4.4 Homecare & OTC Channels
• 5.5 By Distribution Channel
  • 5.5.1 Hospital Pharmacies
  • 5.5.2 Retail Pharmacies & Drug Stores
  • 5.5.3 E-commerce
• 5.6 By Geography
  • 5.6.1 North America
    • 5.6.1.1 United States
    • 5.6.1.2 Canada
    • 5.6.1.3 Mexico
  • 5.6.2 Europe
    • 5.6.2.1 Germany
    • 5.6.2.2 United Kingdom
    • 5.6.2.3 France
    • 5.6.2.4 Italy
    • 5.6.2.5 Spain
    • 5.6.2.6 Rest of Europe
  • 5.6.3 Asia-Pacific
    • 5.6.3.1 China
    • 5.6.3.2 Japan
    • 5.6.3.3 India
    • 5.6.3.4 South Korea
    • 5.6.3.5 Australia
    • 5.6.3.6 Rest of Asia-Pacific
  • 5.6.4 Middle East
    • 5.6.4.1 GCC
    • 5.6.4.2 South Africa
    • 5.6.4.3 Rest of Middle East
  • 5.6.5 South America
    • 5.6.5.1 Brazil
    • 5.6.5.2 Argentina
    • 5.6.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global-level Overview, Market-level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)
  • 6.3.1 AbbVie Inc. (Allergan)
  • 6.3.2 Sientra Inc. / miraDry Inc.
  • 6.3.3 Eli Lilly and Company (Dermira)
  • 6.3.4 Merz Pharma GmbH & Co. KGaA
  • 6.3.5 Brickell Biotech Inc.
  • 6.3.6 Dermavant Sciences Inc.
  • 6.3.7 Candesant Biomedical Inc.
  • 6.3.8 Dermadry Laboratories Inc.
  • 6.3.9 SweatBlock LLC
  • 6.3.10 RA Fischer Co.
  • 6.3.11 Hidrex GmbH
  • 6.3.12 Hidroxa AB
  • 6.3.13 GlaxoSmithKline Consumer Healthcare (Certain Dri)
  • 6.3.14 Carpe Lotions LLC
  • 6.3.15 Strathspey Crown Holdings (Cynosure)
  • 6.3.16 Revance Therapeutics Inc.
  • 6.3.17 Advin Health Care
  • 6.3.18 Dermata Therapeutics Inc.
  • 6.3.19 1315 Capital

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment